Ketamine Therapy for Depression in West Palm Beach is now available at Hope Accelerated Care. Ketamine therapy for depression produces a specific mix of reactions from people who encounter it for the first time: curiosity, skepticism, relief that something new exists, and a reasonable amount of uncertainty about what it actually involves. If you’re researching this treatment, all of those reactions are appropriate — and this article is designed to address them directly.
What follows is a straightforward, evidence-based look at how IV ketamine works for depression, what the clinical experience involves, what the side effects are, who it’s designed for, and what questions to ask before starting. The goal is to give you enough information to approach a clinical consultation as an informed participant rather than starting from scratch.
Why Ketamine Became Part of Psychiatry
Ketamine has been FDA-approved as an anesthetic since 1970. Its application to psychiatric conditions came later, and somewhat unexpectedly: researchers in the early 2000s began studying whether subanesthetic doses — far lower than those used in surgical settings — might produce antidepressant effects. What they found was striking. In controlled clinical studies, patients with treatment-resistant depression showed meaningful reductions in depressive symptoms within hours of a single infusion. (1)
That speed was — and remains — the central clinical surprise. Where standard antidepressants require consistent use over weeks before measurable effects emerge, ketamine’s impact appeared to begin within the treatment window itself. A 2025 systematic review spanning 44 studies confirmed that ketamine significantly reduced depressive symptoms and suicidal ideation within hours, with effects particularly pronounced in treatment-resistant cases. (2)
Ketamine is FDA-approved for anesthetic use; its application in psychiatry is off-label. However, “off-label” doesn’t mean experimental or unsanctioned. Off-label use refers to any use of an FDA-approved drug beyond the specific indications in its original approval. In the case of ketamine, its psychiatric use is extensively documented in peer-reviewed literature, referenced in treatment guidelines from major psychiatric organizations, and practiced by clinicians at academic medical centers and specialty clinics with decades of combined experience.
How It Works — and Why That Matters for TRD
Most antidepressants work on the monoamine system — targeting serotonin, norepinephrine, or dopamine. Ketamine works differently. It acts as an antagonist at NMDA receptors in the glutamate system, the brain’s primary excitatory neurotransmitter pathway, triggering a cascade of neuroplastic changes that researchers believe explains its antidepressant effects. (1)
A 2022 systematic review in Frontiers in Psychiatry found that ketamine promotes synaptogenesis — the formation of new synaptic connections — in brain regions associated with mood regulation, and activates neurotrophic factors that support neural health and recovery. These molecular changes represent a different kind of antidepressant action: not just adjusting chemical levels, but stimulating the brain’s capacity to rewire itself at a structural level.
This is clinically significant for treatment-resistant depression specifically. If a patient’s depression hasn’t responded to multiple antidepressants that all target the monoamine system, the fact that ketamine targets an entirely different pathway means the prior failures don’t predict the response to ketamine. The biology it acts on is different enough that it may reach patients who have not responded to conventional options.
What the Clinical Experience Involves
An IV ketamine infusion is administered in a monitored clinical setting. Before the session begins, the clinical team reviews your current health status, takes baseline vital signs, and confirms that you’ve followed any pre-infusion guidelines regarding food and current medications.
The IV line is placed and the infusion begins at a controlled rate, typically running 45 to 60 minutes. Throughout the session, vital signs — blood pressure, heart rate, oxygen saturation — are monitored by clinical staff. This is standard practice and reflects the care appropriate for any infusion-based medical treatment.
During the infusion, patients commonly experience mild perceptual effects: a sense of mental spaciousness, some visual or sensory shifts, and a temporary loosening of ordinary thought patterns. These effects are a known feature of the ketamine experience and are monitored throughout. For most patients they are not distressing; some describe them as calming or even interesting. They resolve within the session window. A 2025 comprehensive review published in the Annals of Medicine and Surgery confirmed that all observed side effects in clinical IV ketamine administration resolved within an hour after the infusion concluded. (3)
After the infusion, patients rest at the clinic for a monitoring period before being discharged. Because of the transient perceptual effects, driving after a session is not appropriate, and patients should arrange transportation home.
Side Effects and Safety Considerations
The side effects associated with IV ketamine in clinical settings are well-documented and generally transient. The most commonly reported during infusion include mild dissociation, temporary elevation in blood pressure, nausea, and dizziness. (2) These are expected, monitored, and resolve within the session window for the large majority of patients.
The safety concerns most often raised in public conversations about ketamine — addiction potential, bladder damage, cognitive effects — are primarily associated with chronic, high-dose recreational use, not with the controlled, subanesthetic doses used in clinical psychiatric settings. A responsible clinical program includes thorough screening before treatment, including evaluation of substance use history, current medications, and any cardiovascular considerations. Patients with certain diagnoses or medical histories may not be appropriate candidates for IV ketamine, and that determination is made during the evaluation process.
As with any medical treatment, the setting in which ketamine is administered matters considerably. Ketamine infusions delivered in a properly equipped clinical environment by trained staff with monitoring protocols in place carry a meaningfully different risk profile than unmonitored administration. Evaluating a clinic’s clinical team, monitoring standards, and safety protocols is a reasonable part of any patient’s decision-making process.
Who IV Ketamine Is Designed For
IV ketamine therapy is most commonly recommended for adults with treatment-resistant depression — specifically, patients who have not achieved adequate relief from multiple antidepressants. It is also used clinically for patients with major depressive disorder with acute suicidal ideation, where the speed of its action has direct clinical relevance, and for patients with PTSD, anxiety disorders, and OCD that have not responded to conventional treatment.
It is not appropriate for everyone. People with certain psychotic disorders, uncontrolled hypertension, a history of manic episodes (without mood stabilization), or active substance use disorders may not be suitable candidates. A thorough pre-treatment evaluation addresses these considerations and ensures that treatment is recommended only where it’s clinically appropriate and safe.
What to Look for in a Ketamine Clinic
For patients in the West Palm Beach and Palm Beach County area, the growing availability of ketamine therapy means there are real differences in the quality of care available. A few factors are worth assessing. Is the clinic staffed by a psychiatrist or other licensed physician with training specifically in psychiatric ketamine use? Is a thorough intake evaluation conducted before any treatment is recommended? What monitoring protocols are in place during infusion? Is there clinical support available after the session, particularly during the period when the initial treatment effects are wearing off and maintenance planning becomes relevant?
At Hope Therapeutics in West Palm Beach, IV ketamine is offered as part of a broader interventional psychiatry practice — not simply as a standalone service disconnected from the rest of a patient’s care. In some cases, IV ketamine may be the only intervention that we use, depending on our patients’ unique circumstances, but the evaluation that precedes any treatment recommendation is conducted by a clinical team with specific expertise in treatment-resistant presentations. Ketamine, where appropriate, is offered alongside and in coordination with other treatments: TMS, Ketamine-Assisted Psychotherapy, and Medication Management, so that the plan fits the patient’s full clinical picture.
It’s also worth being direct about something patients sometimes wonder: beginning ketamine therapy doesn’t mean ending care you’re already receiving. Many patients continue with their current therapist or psychiatrist throughout — and in many cases, the structured integration of psychotherapy alongside ketamine treatment, known as Ketamine-Assisted Psychotherapy, may support and extend the therapeutic effects of the infusions themselves.
Take the Next Step
If you’re exploring ketamine therapy in the West Palm Beach area, the clinical team at Hope Therapeutics in West Palm Beach can review your treatment history and discuss whether IV Ketamine, SPRAVATO®, TMS, Ketamine-Assisted Psychotherapy, or Medication Management may be appropriate for you.
Hope Therapeutics 1515 N Flagler Dr, Suite 800 | West Palm Beach, FL 33401 📞 561-372-8705 Schedule a Consultation
References
- Kang MJY, Nepomuceno L, et al. The mechanisms behind rapid antidepressant effects of ketamine: a systematic review with a focus on molecular neuroplasticity. Frontiers in Psychiatry. 2022;13:860882. DOI: 10.3389/fpsyt.2022.860882. Available at: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.860882/full
- Peiris TE, Pokhrel A, Paudel Y. Ketamine for unipolar depression: a systematic review of efficacy and safety. The International Journal of Psychiatry in Medicine. 2025. DOI: 10.1177/10398562251328805. Available at: https://journals.sagepub.com/doi/10.1177/10398562251328805
- Lazaridis C, et al. Safety considerations and risk mitigation strategies for ketamine use: a comprehensive review. Annals of Medicine and Surgery. 2025;87(5):2829–2837. DOI: 10.1097/MS9.0000000000003232. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055169/
- Johnson & Johnson. SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression. January 21, 2025. Available at: https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression
The information in this article is intended for educational purposes only and does not constitute medical advice. The treatments described may not be appropriate for every individual. Please consult a qualified healthcare provider to discuss your specific situation, medical history, and treatment options before making any decisions about your care.
